CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2470.0
(0.2%)
KRW 2470.0
(0.2%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 186.85 Billion KRW | 10.33% |
| 2022 | 169.35 Billion KRW | 2445.62% |
| 2021 | 6.65 Billion KRW | 11.2% |
| 2020 | 5.98 Billion KRW | -96.4% |
| 2019 | 166.39 Billion KRW | 61.95% |
| 2018 | 102.74 Billion KRW | 0.04% |
| 2017 | 102.7 Billion KRW | 18.31% |
| 2016 | 86.8 Billion KRW | 80.7% |
| 2015 | 48.04 Billion KRW | -9.7% |
| 2014 | 53.2 Billion KRW | 0.45% |
| 2013 | 52.96 Billion KRW | 3073.94% |
| 2012 | 1.66 Billion KRW | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 186.5 Billion KRW | 39.9% |
| 2024 Q1 | 183.88 Billion KRW | -1.59% |
| 2023 Q3 | 180.65 Billion KRW | -1.27% |
| 2023 Q4 | 186.85 Billion KRW | 3.43% |
| 2023 FY | 242.09 Billion KRW | 13.52% |
| 2023 Q1 | 179.34 Billion KRW | 5.9% |
| 2023 Q2 | 182.98 Billion KRW | 2.03% |
| 2022 Q3 | 6.81 Billion KRW | 4.16% |
| 2022 Q2 | 6.54 Billion KRW | 1.21% |
| 2022 Q1 | 6.46 Billion KRW | -2.79% |
| 2022 Q4 | 169.35 Billion KRW | 2384.2% |
| 2022 FY | 213.26 Billion USD | 7.07% |
| 2021 Q3 | 6.62 Billion KRW | 4.86% |
| 2021 FY | 199.17 Billion USD | 1.95% |
| 2021 Q2 | 6.32 Billion KRW | 2.79% |
| 2021 Q4 | 6.65 Billion KRW | 0.38% |
| 2021 Q1 | 6.14 Billion KRW | 2.78% |
| 2020 Q4 | 5.98 Billion KRW | 6.24% |
| 2020 FY | 195.35 Billion USD | 17.4% |
| 2020 Q1 | 160.96 Billion KRW | -3.26% |
| 2020 Q2 | 5.37 Billion KRW | -96.66% |
| 2020 Q3 | 5.63 Billion KRW | 4.87% |
| 2019 Q2 | 103.92 Billion KRW | 0.97% |
| 2019 Q1 | 102.92 Billion KRW | 0.18% |
| 2019 Q4 | 166.39 Billion KRW | 3.3% |
| 2019 FY | 5.1 Billion USD | 7244.88% |
| 2019 Q3 | 161.08 Billion KRW | 55.0% |
| 2018 Q3 | 101.29 Billion KRW | -0.14% |
| 2018 FY | 2.26 Billion USD | 10.75% |
| 2018 Q4 | 102.74 Billion KRW | 1.43% |
| 2018 Q2 | 101.43 Billion KRW | -3.14% |
| 2018 Q1 | 104.73 Billion KRW | 1.98% |
| 2017 Q4 | 102.7 Billion KRW | 1.71% |
| 2017 FY | 2.04 Billion USD | 0.97% |
| 2017 Q1 | 99.86 Billion KRW | 15.04% |
| 2017 Q2 | 98.62 Billion KRW | -1.25% |
| 2017 Q3 | 100.97 Billion KRW | 2.39% |
| 2016 Q4 | 86.8 Billion KRW | 64.6% |
| 2016 Q2 | 49.86 Billion KRW | -1.15% |
| 2016 Q1 | 50.45 Billion KRW | 5.01% |
| 2016 Q3 | 52.73 Billion KRW | 5.76% |
| 2016 FY | 2.02 Billion USD | -25.65% |
| 2015 Q1 | 52.61 Billion KRW | -1.1% |
| 2015 Q4 | 48.04 Billion KRW | -2.37% |
| 2015 FY | 2.72 Billion USD | 7.82% |
| 2015 Q3 | 49.2 Billion KRW | -3.53% |
| 2015 Q2 | 51 Billion KRW | -3.05% |
| 2014 Q3 | 54.48 Billion KRW | -4.07% |
| 2014 Q1 | 53.87 Billion KRW | 1.73% |
| 2014 FY | 2.52 Billion USD | 25.78% |
| 2014 Q4 | 53.2 Billion KRW | -2.36% |
| 2014 Q2 | 56.79 Billion KRW | 5.41% |
| 2013 FY | 2 Billion USD | 20.41% |
| 2013 Q1 | 51.43 Billion KRW | 2982.34% |
| 2013 Q2 | 50.23 Billion KRW | -2.33% |
| 2013 Q3 | 52.99 Billion KRW | 5.49% |
| 2013 Q4 | 52.96 Billion KRW | -0.06% |
| 2012 Q4 | 1.66 Billion KRW | 0.0% |
| 2012 FY | 1.66 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 141.35 Billion KRW | -32.189% |
| Celltrion Pharm, Inc. | 641.64 Billion KRW | 70.879% |
| Huons Global Co., Ltd. | 1317.96 Billion KRW | 85.823% |
| DongKook Pharmaceutical Co., Ltd. | 839.53 Billion KRW | 77.743% |
| Enzychem Lifesciences Corporation | 211.54 Billion KRW | 11.673% |
| Humedix Co., Ltd. | 219.97 Billion KRW | 15.059% |
| Boditech Med Inc. | 227.9 Billion KRW | 18.012% |
| EuBiologics Co., Ltd. | 172.64 Billion KRW | -8.231% |
| FutureChem Co.,Ltd | 72.83 Billion KRW | -156.548% |
| Huons Co., Ltd. | 537.28 Billion KRW | 65.223% |
| BNC Korea Co., Ltd. | 236.15 Billion KRW | 20.877% |
| AptaBio Therapeutics Inc. | 92.51 Billion KRW | -101.96% |